Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Investor Presentation
Q2 FY24
Investor Presentation
Q2 FY23
Investor Presentation
Q4 FY18
Bearish
9
Neutral
2
Bullish
3
Bearish
15
Neutral
2
Bullish
29
Bearish
6
Neutral
0
Bullish
26
Bearish
6
Neutral
0
Bullish
26
Bearish
6
Neutral
0
Bullish
26
Bearish
6
Neutral
0
Bullish
26
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1097.40 | 10,115 Cr | 15.88 | 3.25 | 0.46 | 17.90 | 17.30 | 9.16 | ||
224.85 | 9,933 Cr | 46.46 | 3.52 | 0.00 | 7.07 | 13.01 | 5.77 | ||
503.85 | 9,537 Cr | 40.60 | 4.42 | 0.22 | 18.22 | 24.16 | 14.31 | ||
5510.60 | 9,147 Cr | 25.63 | 17.44 | 3.72 | 62.32 | 84.14 | 42.42 | ||
927.55 | 8,411 Cr | 32.77 | 3.73 | 0.38 | 8.22 | 9.59 | 6.12 | ||
1252.25 | 8,046 Cr | 69.76 | 6.19 | 0.00 | 9.56 | 11.55 | — | ||
3467.95 | 7,987 Cr | 28.56 | 22.96 | 2.16 | 76.46 | 92.74 | 39.60 | ||
| Median: 7 Co. | — | 1097.40 | 9,147 Cr | 32.77 | 4.42 | 0.38 | 17.90 | 17.30 | 11.74 |
Procter & Gamble Health Limited is an Indian pharmaceutical and consumer healthcare company focused on manufacturing and marketing science‑backed vitamins, minerals and supplements (VMS), prescription and OTC formulations; its portfolio includes established brands such as Neurobion, Livogen, Evion, Seven Seas, Polybion and Nasivion, plus three recent innovations introduced in 2026.
The company reported fiscal year sales of approximately ₹1,400 crore, up about 16% year‑on‑year, and Profit After Tax of ₹327 crore, up roughly 30%, driven by integrated strategy execution across product superiority, retail execution and productivity programmes that delivered around ₹35 crore of savings during the year.
In FY26 Procter & Gamble Health Limited launched three significant innovations—Livogen Iron Gummies, Neurobion Nerve Pain Relief Cream and Evion L5000—that collectively contributed early single‑digit points of incremental growth and are already showing strong e‑commerce and HCP traction, with Livogen Gummies ranking #1 in its Amazon category.
A recent structural go‑to‑market change materially expanded reach, adding nearly 30,000 pharmacies and HCPs and improving penetration into extra‑urban geographies; management highlights mid‑single digit volume growth, accelerating e‑commerce adoption and export recovery, including strong growth in Nepal and Sri Lanka.
Management’s integrated growth strategy centers on five pillars—portfolio superiority, superior packaging and communications, retail execution, productivity to fund reinvestment, and constructive disruption—aimed at sustaining balanced top‑line and margin expansion while reinvesting for innovation and HCP engagement.
Pharmaceuticals & Biotechnology
Pharmaceuticals
9,147 Cr
Low Risk
25.6
37.0
3.4
17.4
6,955.00
4,699.70
Sales CAGR
Profit CAGR
ROE
ROCE
Upcoming Result Date: Nov 01, 2026
Procter & Gamble Health Ltd (PGHL) is currently trading at 5,697.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Procter & Gamble Health Limited is an Indian pharmaceutical and consumer healthcare company focused on manufacturing and marketing science‑backed vitamins, minerals and supplements (VMS), prescription and OTC formulations; its portfolio includes established brands such as Neurobion, Livogen, Evion, Seven Seas, Polybion and Nasivion, plus three recent innovations introduced in 2026. The company reported fiscal year sales of approximately ₹1,400 crore, up about 16% year‑on‑year, and Profit After Tax of ₹327 crore, up roughly 30%, driven by integrated strategy execution across product superiority, retail execution and productivity programmes that delivered around ₹35 crore of savings during the year. In FY26 Procter & Gamble Health Limited launched three significant innovations—Livogen Iron Gummies, Neurobion Nerve Pain Relief Cream and Evion L5000—that collectively contributed early single‑digit points of incremental growth and are already showing strong e‑commerce and HCP traction, with Livogen Gummies ranking #1 in its Amazon category. A recent structural go‑to‑market change materially expanded reach, adding nearly 30,000 pharmacies and HCPs and improving penetration into extra‑urban geographies; management highlights mid‑single digit volume growth, accelerating e‑commerce adoption and export recovery, including strong growth in Nepal and Sri Lanka. Management’s integrated growth strategy centers on five pillars—portfolio superiority, superior packaging and communications, retail execution, productivity to fund reinvestment, and constructive disruption—aimed at sustaining balanced top‑line and margin expansion while reinvesting for innovation and HCP engagement.
Over the past 52 weeks, Procter & Gamble Health Ltd has traded between a low of ₹4,699.70 and a high of ₹6,955.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Procter & Gamble Health Ltd has a market capitalization of approximately 9,147.26. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Procter & Gamble Health Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 25.63 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 9,147.26 Cr, Procter & Gamble Health Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Procter & Gamble Health Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Procter & Gamble Health Ltd is 25.63. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Standalone net profit for Q1 FY27 was ₹96.15 crore, up 45% from ₹66.18 crore in Q1 FY26.
Procter & Gamble Health reported standalone net profit of ₹96.15 crore in Q1 FY27, up 45% from ₹66.18 crore in Q1 FY26.
Management cited sales of about ₹4,300 crore (flat year-on-year) and PAT of about ₹850 crore, while the audited summary cited sales of ₹4,290 crore and PAT of ₹857 crore for FY26.
Based on financial forecasts and market trends, the share price for Procter & Gamble Hygiene and Health Care is projected to reach a maximum target of ₹24,000 by the end of 2030, assuming continued operational performance.
